Emerging and future therapies for the treatment of bone loss associated with chronic inflammation

Inflammopharmacology

Volumn 14, Issue 5-6, 2006, Pages 193-197

  Haynes, D R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bone pathology; Chronic inflammation; Osteoclast inhibitors; Osteoclasts

Indexed keywords

ALENDRONIC ACID; BENOXAPROFEN; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CASPASE 8; CLOBUZARIT; CYCLOOXYGENASE 2 INHIBITOR; DENOSUMAB; ETIDRONIC ACID; FAS ASSOCIATED DEATH DOMAIN PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2; PROTEIN C JUN; PROTEIN KINASE B; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADJUVANT ARTHRITIS; BONE ATROPHY; BONE DESTRUCTION; BONE NECROSIS; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; CONFERENCE PAPER; ENZYME INHIBITION; HUMAN; NONHUMAN; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CHRONIC DISEASE; DIPHOSPHONATES; HUMANS; OSTEOCLASTS; PERIODONTAL DISEASES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 33845867417     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-006-0006-1     Document Type: Conference Paper

References (41)

1. Abrahamsen, B. and Teng, A. Y. (2005). Technology evaluation: denosumab, Amgen. Curr. Opin Mol. Ther. 7, 604-610.
2. Albandar, J. M. and Rams, T. E. (2002). Global epidemiology of periodontal diseases: an overview. Periodontol 2000, 29, 7-10.
3. Benslay, D. N. and Nickander, R. (1982). Comparative effects of benoxaprofen and other anti-inflammatory drugs on bone damage in the adjuvant arthritic rat. Agents Actions 12, 313-319.
4. Bhandari, M., Bajammal, S., Guyatt, G. H., Griffith, L., Busse, J. W., Schunemann, H. and Einhorn, T. A. (2005). Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J. Bone Joint Surg. Am. 87, 293-301.
5. Bokarewa, M., Lindblad, S., Bokarew, D. and Tarkowski, A. (2005) Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res. Ther. 7, R349-R358.
6. Cantwell, M. J., Hua, T., Zvaifler, N. J. and Kipps, T. J. (1997). Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 40, 1644-1652.
7. Cheng, A., Mavrokokki, A., Carter, G., Stein, B., Fazzalari, N. L., Wilson, D. F. and Goss, A. N. (2005). The dental implications of bisphosphonates and bone disease. Aust. Dent. J. 50, S4-S13.
8. Crotti, T., Smith, M. D., Hirsch, R., Soukoulis, S., Weedon, H., Capone, M., Ahern, M. J. and Haynes, D. (2003). Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J. Periodontal Res. 38, 380-387.
9. Crotti, T. N., Smith, M. D., Findlay, D. M., Zreiqat, H., Ahern, M. J., Weedon, H., Hatzinikolous, G., Capone, M., Holding, C. and Haynes, D. R. (2004). Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 25, 565-573.
10. Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M. C., Tak, P. P. and Haynes, D. R. (2002). Receptor activator NF kB ligand (RANKL) expression in synovial tissue from rheumatoid arthritis, spondyloarthropathy, osteoarthritis and normal patients: semi-quantitative and quantitative analysis. Ann. Rheum. Dis. 61, 0-7.
11. David, J. P., Sabapathy, K., Hoffmann, O., Idarraga, M. H. and Wagner, E. F. (2002). JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115, 4317-4325.
12. Emery, J. G., Mcdonnell, P., Burke, M. B., C.Deen, K., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., Diprinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C. and Young, P. R. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biology Chemistry 273, 14363-14367.
13. Han, Z., Boyle, D. L., Chang, L., Bennett, B., Karin, M., Yang, L., Manning, A. M. and Firestein, G. S. (2001). c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108, 73-81.
14. Haynes, D. R. and Crotti, T. N. (2003). Regulation of bone lysis in inflammatory diseases. Inflammopharmacology 11, 323-331.
15. Kaminska, B. (2005). MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754, 253-262.
16. Kim, H. H., Shin, H. S., Kwak, H. J., Ahn, K. Y., Kim, J. H., Lee, H. J., Lee, M. S., Lee, Z. H. and Koh, G. Y. (2003). RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/ Akt signal transduction pathway. Faseb J. 17, 2163-2165.
17. Kim, Y., Sato, K., Asagiri, M., Morita, I., Soma, K. and Takayanagi, H. (2005). Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J. Biol. Chem. 280, 32905-32913.
18. Kimberley, F. C. and Screaton, G. R. (2004). Following a TRAIL: Update on a ligand and its five receptors. Cell Research. 14, 359-372.
19. Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliot, R., Colombero, A., Elliot, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Caparelli, C., Eli, A., Qian, Y.-X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
20. Lee, Z. H. and Kim, H. H. (2003). Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211-214.
21. Malchau, H., Herberts, P. and Ahnfelt, L. (1993). Prognosis of total hip replacement in Sweden. Acta Orthop. Scand. 64, 497-506.
22. Mangan, D. F., Mergenhagen, S. E. and Wahl, S. M. (1993). Apoptosis in human monocytes: possible role in chronic inflammatory diseases. J. Periodontol. 64, 461-466.
23. Martin, T. J. and Ng, K. W. (1994). Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J. Cell Biochem. 56, 357-366.
24. Nesterov, A., Ivaschenko, Y. and Kraft, A. S. (2002). Tumour necrosis factor related-apoptosis-inducing ligand(TRAIL) triggers apoptosis in normal epithelial cells. Nature 21, 1135-1140.
25. Page, R. C., Offenbacher, S., Schroeder, H. E., Seymour, G. J. and Kornman, K. S. (1997). Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol. 2000, 14, 216-248.
26. Pauletto, N., Silver, J. G. and Larjava, H. (1997). Nonsteroidal anti-inflammatory agents: potential modifiers of periodontal disease progression. J. Can. Dent. Assoc. 63, 824-829, 832.
27. Pettersen, I., Figenschau, Y., Olsen, E., Bakkelund, W., Smedsrod, B. and Sveinbjornsson, B. (2002). Tumor necrosis factor- related apoptosis-inducing ligand induces apoptosis in human articular chondrocytes in vitro. Biochemical and Biophysical Research Communication 296IX, 00916-6.
28. Pitti, R., Marsters, S., Ruppert, S., Donahue, C., Moore, A. and Ashkenazi, A. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690.
29. Rodan, G. A. and Martin, T. J. (1982). Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif Tissue Int. 34, 311.
30. Shanbhag, A. S. (2006). Use of bisphosphonates to improve the durability of total joint replacements. J. Am. Acad. Orthop. Surg. 14, 215-225.
31. Shen, Z., Crotti, T. N., Mchugh, K. P., Matsuzaki, K., Gravallese, E. M., Bierbaum, B. E. and Goldring, S. R. (2006). The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis. Arthritis Res. Ther. 8, R70.
32. Shin, S., Sung, B. J., Cho, Y. S., Kim, H. J., Ha, N. C., Hwang, J. I., Chung, C. W., Jung, Y. K. and Oh, B. H. (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40, 1117-1123.
33. Smith, M. D. and Walker, J. G. (2004). Apoptosis a relevant therapeutic target in rheumatoid arthritis? Rheumatology (Oxford) 43, 405-407.
34. Szodoray, P., Jellestad, S., Nakken, B., Brun, J. G. and Jonsson, R. (2003). Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. Lab Invest. 83, 1839-1848.
35. Tak, P. P. and Firestein, G. S. (2001). NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107, 7-11.
36. Takeda, K., Smyth, M., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H. and Okumura, K. (2002). Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169.
37. Urnowey, S., Ansai, T., Bitko, V., Nakayama, K., Takehara, T. and Barik, S. (2006). Temporal activation of anti- and pro-apoptotic factors in human gingival fibroblasts infected with the periodontal pathogen. Porphyromonas gingivalis: potential role of bacterial proteases in host signalling. BMC Microbiol. 6, 26.
38. Wiley, S., Schooley, K., Smolak, P., Ws Din, Huang, C., Nicholl, J., Gr Sutherland, Td, S., Rauch, C. and Ca Smith, E. A. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
39. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T. and Higashio, K. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337.
40. Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C. and Secchiero, P. (2004). TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104, 2044-2450.
41. Zhang, Q., Badell, I. R., Schwarz, E. M., Boulukos, K. E., Yao, Z., Boyce, B. F. and Xing, L. (2005). Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum. 52, 2708-2718.